Brief: Natera Says To Present 14 Studies At ESMO, Including Imvigor011 Oral Presentation
12/10/2025 23:13
Oct 12 (Reuters) - Natera Inc NTRA.O: NATERA INC: NATERA TO PRESENT 14 STUDIES AT ESMO, INCLUDING IMVIGOR011 ORAL PRESENTATION NATERA INC - SIX ORAL PRESENTATIONS HIGHLIGHT SIGNATERA'S ROLE IN SOLID TUMORS NATERA: ADDITIONAL ORAL PRESENTATIONS INCLUDE RESULTS FROM SUNRISE-4 TRIAL , INTERCEPT TRIAL IN COLORECTAL CANCER, & NATERA'S EARLY CANCER DETECTION PROGRAM Source text: ID:nBw91mSkra Further company coverage: NTRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers